文献速递血栓与止血白血病淋巴瘤

阿哌沙班对比无抗凝治疗用于新诊断急性淋巴细胞白血病或淋巴瘤儿童静脉血栓栓塞预防(PREVAPIX-ALL):一项3期、开放标签、随机、对照试验

Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial.
PubMed 文献 · Lancet Haematol · 2023-11-16

PREVAPIX-ALL是一项在9个国家74家儿科医院开展的3期开放标签随机对照试验,纳入512例新诊断急性淋巴细胞白血病或淋巴瘤且留置中心静脉导管的患儿,1:1随机接受标准治疗(无系统抗凝)或体重调整阿哌沙班。阿哌沙班组复合静脉血栓栓塞发生31/256(12%),标准治疗组45/256(18%),RR 0.69(95%CI 0.45-1.05;P=0.080),无统计学显著获益;大出血两组各2例;临床相关非大出血阿哌沙班组11/256(4%)高于标准治疗组3/256(1%)(RR 3.67,95%CI 1.04-12.97,P=0.030)。

要点

  • 阿哌沙班组复合静脉血栓栓塞12% vs 标准治疗组18%,RR 0.69(95%CI 0.45-1.05;P=0.080),无统计学显著差异。
  • 大出血两组各2例(RR 1.0,95%CI 0.14-7.01;P=1.0)。
  • 临床相关非大出血阿哌沙班组4% vs 标准治疗组1%(RR 3.67,95%CI 1.04-12.97;P=0.030),主要为1或2级鼻出血。

核心结论

  • 阿哌沙班治疗未发现统计学显著获益。
  • 大出血和临床相关非大出血总体不常见,但阿哌沙班组临床相关非大出血发生率更高,主要为年幼儿童鼻出血。
  • 对于被认为血栓风险特别高的患者,PREVAPIX-ALL为在潜在获益被认为大于出血风险的临床情境中使用阿哌沙班提供了令人鼓舞的安全性数据。

研究设计与样本

  • PREVAPIX-ALL为3期、开放标签、随机、对照试验,在9个国家74家儿科医院开展。
  • 纳入年龄1岁及以上至18岁以下、新诊断急性淋巴细胞白血病(前B细胞或T细胞)或淋巴母细胞淋巴瘤(B细胞或T细胞免疫表型)且诱导期间全程留置中心静脉导管的患者。
  • 按1:1随机分配至标准治疗(即无系统抗凝)或体重调整每日两次阿哌沙班,随机化集中进行并按年龄(<10岁或≥10岁)分层。
  • 体重≤35 kg者接受阿哌沙班2.5 mg每日两次(2.5 mg片剂、0.5 mg片剂或0.4 mg/mL口服溶液),体重>35 kg者使用0.5 mg片剂或0.4 mg/mL口服溶液按体重调整预防剂量每日两次。
  • 主要结局由盲法中心裁决委员会评估;主要疗效结局为意向治疗人群症状性或临床未怀疑静脉血栓栓塞的复合终点,主要安全性结局为大出血,次要安全性结局包括临床相关非大出血。

主要发现

  • 2015年10月22日至2021年6月4日随机分配512例参与者并纳入分析(女性222例[43%],男性290例[57%];白人388例[76%],亚洲人52例[10%],黑人或非裔美国人24例[5%],其他种族48例[9%];西班牙裔或拉丁裔122例[24%])。
  • 中位随访27天(IQR 26-28)期间,阿哌沙班组256例中31例(12%)发生复合静脉血栓栓塞,标准治疗组256例中45例(18%)发生(相对风险[RR] 0.69,95%CI 0.45-1.05;P=0.080)。
  • 大出血两组各发生2例(RR 1.0,95%CI 0.14-7.01;P=1.0)。
  • 临床相关非大出血阿哌沙班组发生率更高(11/256[4%]),标准治疗组为3/256(1%)(RR 3.67,95%CI 1.04-12.97,P=0.030),主要为1或2级鼻出血。
  • 两组最常见的3-5级不良事件为血小板减少症(阿哌沙班组n=28,标准治疗组n=20)或血小板计数降低(n=49和n=45)、贫血(n=77和n=74)、发热性中性粒细胞减少症(n=27和n=20)、中性粒细胞减少症(n=16和n=17)或中性粒细胞计数降低(n=22和n=25)。

关键数值与推荐

  • 主要疗效结局:阿哌沙班组31/256(12%)vs 标准治疗组45/256(18%),RR 0.69(95%CI 0.45-1.05;P=0.080)。
  • 主要安全性结局大出血:阿哌沙班组2/256 vs 标准治疗组2/256,RR 1.0(95%CI 0.14-7.01;P=1.0)。
  • 临床相关非大出血:阿哌沙班组11/256(4%)vs 标准治疗组3/256(1%),RR 3.67(95%CI 1.04-12.97;P=0.030)。
  • 体重≤35 kg者阿哌沙班剂量为2.5 mg每日两次;体重>35 kg者按体重调整预防剂量每日两次。

临床怎么用

  • 对于被认为血栓风险特别高的患者,PREVAPIX-ALL为在潜在获益被认为大于出血风险的临床情境中使用阿哌沙班提供了令人鼓舞的安全性数据。
  • 阿哌沙班组临床相关非大出血发生率更高,主要为年幼儿童鼻出血。

局限性

  • 阿哌沙班组复合静脉血栓栓塞12% vs 标准治疗组18%,RR 0.69(95%CI 0.45-1.05;P=0.080),未达统计学显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Paediatric patients with acute lymphoblastic leukaemia or lymphoma are at increased risk of venous thromboembolism resulting in increased mortality and morbidity. We hypothesised that apixaban, a direct oral anticoagulant, would safely reduce venous thromboembolism in this patient population. METHODS: PREVAPIX-ALL was a phase 3, open-label, randomised, controlled trial conducted in 74 paediatric hospitals in 9 countries. Participants aged 1 year or older to younger than 18 years with newly diagnosed acute lymphoblastic leukaemia (pre-B cell or T cell) or lymphoblastic lymphoma (B cell or T cell immunophenotype) and a central venous line in place throughout induction were randomly assigned 1:1 to standard of care (SOC, ie, no systemic anticoagulation) or weight-adjusted twice-daily apixaban during induction. Randomisation was performed centrally and stratified by age (those <10 years or those ≥10 years). Participants weighing 35 kg or less were administered 2·5 mg twice daily of apixaban as a 2·5 mg tablet, 0·5 mg tablets, or 0·4 mg/mL oral solution, while those weighing more than 35 kg were administered weight-adjusted prophylactic doses using 0·5 mg tablets or the 0·4 mg/mL oral solution twice daily. Primary outcomes were assessed by a blinded central adjudication committee. The primary efficacy outcome for the intention to treat population was the composite of symptomatic or clinically unsuspected venous thromboembolism, the primary safety outcome was major bleeding, and secondary safety outcomes included clinically relevant non-major (CRNM) bleeding. Patients were screened for venous thromboembolism by ultrasound and echocardiogram at the end of induction. The trial was registered with ClinicalTrials.gov (NCT02369653) and is now complete. FINDINGS: Between Oct 22, 2015, and June 4, 2021, 512 participants were randomly assigned and included in analyses (222 [43%] female and 290 [57%] male; 388 [76%] White, 52 [10%] Asian, 24 [5%] Black or African American, and 48 [9%] other races; and 122 [24%] Hispanic or Latino ethnicity). During a median follow-up period of 27 days (IQR 26-28), 31 (12%) of 256 patients on apixaban had a composite venous thromboembolism compared with 45 (18%) of 256 participants receiving SOC (relative risk [RR] 0·69, 95% CI 0·45-1·05; p=0·080). Two major bleeding events occurred in each group (RR 1·0, 95% CI 0·14-7·01; p=1·0). A higher incidence of CRNM bleeding, primarily grade 1 or 2 epistaxis, occurred in the apixaban group (11 [4%] of 256 participants) compared with the SOC group (3 [1%] of 256; RR 3·67, 95% CI 1·04-12·97, p=0·030). The most frequent grade 3-5 adverse events in both groups were thrombocytopenia (n=28 for the apixaban group and n=20 for the SOC group) or platelet count decreased (n=49 and n=45), anaemia (n=77 and n=74), febrile neutropenia (n=27 and n=20), and neutropenia (n=16 and n=17) or neutrophil count decreased (n=22 and n=25). Five deaths occurred, which were due to infection (n=3 in the SOC group), cardiac arrest (n=1 in apixaban group), and haemorrhagic cerebral sinus vein thrombosis (n=1 in the SOC group). There was one apixaban-related death (coagulopathy and haemorrhage after cardiac arrest of unknown cause). INTERPRETATION: PREVAPIX-ALL is, to our knowledge, the first trial assessing primary thromboprophylaxis using a direct oral anticoagulant in paediatric patients with acute lymphoblastic leukaemia or lymphoma. No statistically significant treatment benefit was identified in participants receiving apixaban. Major and CRNM bleeding were infrequent overall, but a higher incidence of CRNM bleeding (primarily epistaxis in younger children) occurred in participants receiving apixaban. For patients deemed to be at particularly high risk of thrombosis, PREVAPIX-ALL provides encouraging safety data for the use of apixaban in clinical settings in which the potential benefits are thought to outweigh the risk of bleeding. FUNDING: Bristol Myers Squibb-Pfizer Alliance.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. O'Brien SH, Rodriguez V, Lew G, et al. Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial. Lancet Haematol. 2023. PMID: 37980924. doi:10.1016/S2352-3026(23)00314-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。